In the PROVE-HF trial, improved markers of cardiac function, volume decrease, and a reduction in the circulating levels of NT-proBNP were reported in subjects with HF with decreased ejection fraction that underwent treatment using sacubitril/valsartan [66]. Here, NPPB is linked to hydrops fetalis.